key: cord-0951264-1x2zcbgg authors: Usmani, Salman Sadullah; Raghava, Gajendra P. S. title: Potential Challenges for Coronavirus (SARS-CoV-2) Vaccines Under Trial date: 2020-09-29 journal: Front Immunol DOI: 10.3389/fimmu.2020.561851 sha: f70282860ec82a8618ddfcc12d3ac097fdbd9a6a doc_id: 951264 cord_uid: 1x2zcbgg nan activation. ChAdOx1 has already started phase 3 clinical trials, after showing an acceptable safety profile in single blind, randomized phase 1/2 clinical trials (6) . Inovio Pharmaceuticals, a US-based biotechnology firm, has developed INO-4800, a DNA-based vaccine, utilizing a relatively newer vaccine technique. Here, DNA containing the genetic code of SARS-CoV-2 spike proteins will be injected into human cells by electroporation devices, and the transformed spike proteins will activate the immune system. PiCoVacc, currently in phase 3 trial, is an inactivated vaccine developed by Sinovac, a Chinese private biopharma company, based on the traditional fact that exposure to an inactivated virus will eventually lead up to the immune response (7) . The Beijing Institute of Biological Products/Wuhan Institute of Biological Products is working on few inactivated vaccines, which are in the clinical phases 2/3. However, they are relatively unadvertised outside Chinese media (8) . Besides this, two RNA vaccines are also in the pipeline, named as mRNA-1273 by US biotech firm Moderna/ NIAID and BNT-162 jointly by German company BioNTech and US pharma giant Pfizer. Both these vaccines follow the concept of delivering information molecules to instruct human body cells to produce the spike proteins of SARS-CoV-2. This information molecule is mRNA in the case of BNT-162, whereas LNPencapsulated mRNA in mRNA-1273 (9, 10) ( Figure 1 ). The current distressing worldwide scenario demands a vaccine at the earliest, causing a race among pharmaceutical industries. This accelerated version of vaccine development implements parallel steps like animal testing, clinical phase 1, or simultaneous phase 1 and 2 clinical trials. By involving several manufacturers, the developers of ChAdOx1 have already planned to produce a million-dose by September 2020 (11) . However, the question is whether speeding the trail is safe. What are the possibilities of getting a vaccine with the highest efficacy concerning diverse ages and ethnicity? What is the financial risk in scaling up production capacity, even before sufficient efficacy data, like in the case of ChAdOx1? These questions make sense if we re-evaluate recent virus outbreaks, including Ebola, Zika, or earlier coronaviruses, i.e., SARS and MERS. The Ebola and Zika epidemics ended before vaccine development, leaving the manufacturer with financial loss due to the reallocation of funds by federal agencies (12) . The SARS (severe acute respiratory syndrome) coronavirus emerged in 2002-03 and affected 26 countries, whereas the MERS (Middle East respiratory syndrome) coronavirus emerged in 2012 and affected 27 countries (13) . However, the astonishing fact is that no vaccine has been commercially available for these coronaviruses until now (14) . Inactivated SARS virus (15) , live attenuated/host-adapted SARS virus (16) , replicating and nonreplicating viral vector (17, 18) , DNA based vaccine (19) , soluble proteins/adjuvants (20) , virus-like peptide/adjuvants (21) , and a combination of vaccines approach (22, 23) have been used to develop a vaccine against SARS-CoV, but to the best of our knowledge only inactivated SARS virus, DNA and soluble SARS S-glycoprotein reached the clinical phase 1 trials (14) . Similarly, for MERS, several vaccines have been developed, but only a DNA based vaccine, targeting S-glycoproteins and subunits, is in a clinical phase 1 trial (24) . The vaccine development might have been slowed by several reasons such as a lack of suitable animal Frontiers in Immunology | www.frontiersin.org September 2020 | Volume 11 | Article 561851 models, as they exhibited limited viral replication and clinical manifestations (25) or geographically centralized cases might have declined the interest of pharmaceutical companies. Whatever the reason for the lack of vaccine or financial losses, there is a need to revisit these cases while investing in the development of the SARS-CoV-2 vaccine. The nature of COVID-19 transmission makes it more devastating, as the median incubation time from infection to symptoms ranges from 4-7 days. Besides this, many infected patients remain asymptomatic but prone to transmit the virus (26) . It is quite evident that both innate and adaptive immunity plays a role during the COVID-19 infection, but how their interaction mediates viral control as well as host toxicity, is not very clear yet. Based on pieces of evidence, it has been suggested that an innate immune-mediated 'cytokine storm' is responsible for toxicity and organ damage in a subgroup of patients with a severe COVID-19 infection (27) . Extended populations of IL-6 and IL-1b secreting monocytes have been found in COVID-19 infected patients, resulting in elevated serum IL-6 and lactate dehydrogenase, a marker of pyroptosis, a highly inflammatory form of programmed cell death (28, 29) . Similarly, an elevated level of ferritin and IL-6 in 150 multicenter COVID-19 confirmed cases suggested that virally driven hyper-inflammation might be the reason for mortality (30) . It is a known fact that virally derived pathogen and damage-associated molecular patterns (PAMP and DAMP) activate macrophages, resulting in the downstream production of IL-6 and IL-1b, which further recruits neutrophils and CD8 + T cells, thus controlling viral growth. However, within the lung parenchyma, neutrophils also induce tissue damage by releasing leukotrienes and reactive oxygen species, giving passage to alveolar flooding and fibrosis. In severe infection, persistent IL-6 elevation leads to constant neutrophil-mediated alveolar damage, resulting in the need for mechanical ventilation and, ultimately, mortality (31) . We all know that an early innate and adaptive immune response leads to the suppression of acute viral infection. However, chronic viral infection causes T cell depletion and exhaustion, leaving persistent innate activation, triggering inflammation, and cytokine toxicity. An intact T cell-mediated immune response is the key contributor in clearing and maintaining long term suppression (32) . It is a growing possibility that immunosuppression due to the depletion and exhaustion of T cells contribute to COVID-19 persistence and mortality (27, 33) . There are several studies showing a paradoxical phenomenon, in which vaccinated animals or people exhibit a more severe disease while exposed to the virus than non-activated fellows (34) (35) (36) . This immune backfiring is known as antibody dependent enhancement (ADE), in which the virus influences antibodies for its own benefit and enhances the infection or immune enhancement, consisting of allergic inflammation due to Th2 immunopathology. ADE has been observed with dengue, HIV, flavivirus, as well as Zika virus (37) (38) (39) (40) . The hunt for a SARS and MERS vaccine has been stymied by ADE. It has been shown that, antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins (41, 42) . ADE or eosinophilmediated immunopathology has been observed while immunizing mice with inactivated whole SARS-CoV (43) or DNA vaccine encoding full length S-protein (44) as well as immunizing macaque models with MVA encoded S protein (45) . There have been various recently published articles concerning the potential danger of suboptimal antibody responses or ADE of SARS-CoV-2, providing an insightful discussion (46) (47) (48) (49) . It is obvious to consider the fact that both an innate and adaptive immunity participates in COVID-19 mediated toxicity while designing vaccines. There is always a possibility of mutation within a human genome by nucleic acid vaccines (50) . What if the spike proteins contain the region which could elicit the IL-6 or IL-1b level? What if the nucleic acid fragment delivered within the body transforms into a region of spike proteins that are proinflammatory or have any other interleukin-inducing peptides? There are significant possibilities of having toxic peptide fragments in COVID-19 spike proteins. The peptide region may have hemolytic potential, resulting in hemolysis as a severe side effect. Besides this, the coronavirus spike protein may contain the regions prone to allergy, and their processing inside the cell may lead to allergic antigens. Have they been ruled out, while delivering spike protein regions into the body? Bioinformatics might provide an answer to these queries to some extent. There are several in silico tools to predict interleukin-inducing properties, pro/anti-inflammatory as well as the toxicity of peptides (51) (52) (53) (54) (55) (56) (57) (58) (59) (60) . Besides this, many in silico tools are available for designing subunit vaccines and immunotherapeutics (61, 62) . There are 244,682 proteins and 22,892 nucleotide sequence information about SARS-CoV-2 available in the NCBI virus datahub, as of September 8, 2020 (63) . It is obvious that all 244,682 proteins cannot be a vaccine candidate, so we can use various in silico tools to identify potential vaccine candidates. These candidates must be further scrutinized for potential epitopes, which can activate the desired arm of the immune system. The half-life, toxicity, and unwanted properties like in SARS-CoV-2 cases such as IL-6 inducing potential, immunosuppressive property, hemolysis, and allergy must also be checked. We have enlisted some useful in silico tools in Figure 1 . Various researchers have already identified potential B and T cell epitopes, HLA susceptibility mapping as well as candidate targets by applying a bioinformatic approach (64) (65) (66) (67) (68) (69) . In the cat and mouse game of a viral pandemic and vaccine development, bioinformatic resources are beneficial and will cut down the chances of failure, a lesson by previous virus endemics. There are significant chances of severe side effects, as the frenetic race against time forced the vaccine trials on a fast track. Due to emergency and the worldwide crisis, there is a possibility of accelerating the trial mechanism by reducing numbers and waving off some of the population, as reported in several news agencies (70, 71) . We hope that the devastating worldwide scenario will end up with a successful vaccine candidate soon. SU wrote the manuscript while GR conceived the idea as well as edited the manuscript. Coronavirus Disease (COVID-19) Coronavirus: A visual guide to the economic impact Scores of coronavirus vaccines are in competition -how will scientists choose the best? Draft landscape of COVID-19 candidate vaccines A Review of SARS-CoV-2 and the Ongoing Clinical Trials Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial Development of an inactivated vaccine candidate for SARS-CoV-2 China Focus: China's inactivated COVID-19 vaccine starts phase-3 clinical trial internationally UK COVID-19 vaccine candidate to be manufactured at seven outsourced sites Developing Covid-19 Vaccines at Pandemic Speed SARS and MERS: recent insights into emerging coronaviruses Vaccines for SARS-CoV-2: Lessons from Other Coronavirus Strains Safety and immunogenicity from a phase I trial of inactivated severe acute respiratory syndrome coronavirus vaccine Immunization with an attenuated severe acute respiratory syndrome coronavirus deleted in E protein protects against lethal respiratory disease Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets Severe acute respiratory syndrome vaccine efficacy in ferrets: whole killed virus and adenovirus-vectored vaccines A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice A recombinant baculovirus-expressed S glycoprotein vaccine elicits high titers of SARS-associated coronavirus (SARS-CoV) neutralizing antibodies in mice Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus Priming with SARS CoV S DNA and boosting with SARS CoV S epitopes specific for CD4+ and CD8+ T cells promote cellular immune responses Priming with rAAV encoding RBD of SARS-CoV S protein and boosting with RBD-specific peptides for T cell epitopes elevated humoral and cellular immune responses against SARS-CoV infection Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial Development of animal models against emerging coronaviruses: From SARS to MERS coronavirus Clinical features of patients infected with 2019 novel coronavirus in Wuhan COVID-19: consider cytokine storm syndromes and immunosuppression Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing COVID-19 infection induces readily detectable morphological and inflammation-related phenotypic changes in peripheral blood monocytes, the severity of which correlate with patient outcome. medRxiv (2020) Correction to: Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan The many faces of the anti-COVID immune response Viral infection of the lung: host response and sequelae COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome? In vivo enhancement of dengue virus infection in rhesus monkeys by passively transferred antibody Antibody-dependent enhancement (ADE) of porcine reproductive and respiratory syndrome virus (PRRSV) infection in pigs Antibody-dependent enhancement of virus infection and disease Antibody-dependent enhancement and the risk of HIV infection Fc receptors in antibody-dependent enhancement of viral infections Antibody-dependent enhancement of severe dengue disease in humans Antibody-Dependent Enhancement and Zika: Real Threat or Phantom Menace? Anti-severe acute respiratory syndrome coronavirus spike antibodies trigger infection of human immune cells via a pH-and cysteine protease-independent FcgammaR pathway Antibodydependent SARS coronavirus infection is mediated by antibodies against spike proteins A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection A perspective on potential antibody-dependent enhancement of SARS-CoV-2 Antibody Dependent Enhancement Due to Original Antigenic Sin and the Development of SARS COVID-19 vaccine design: the Janus face of immune enhancement The potential danger of suboptimal antibody responses in COVID-19 COVID-19: Therapeutics and Their Toxicities AlgPred: prediction of allergenic proteins and mapping of IgE epitopes Prediction of IL4 inducing peptides In silico approach for predicting toxicity of peptides and proteins AllerTOP v.2-a server for in silico prediction of allergens Computer-aided designing of immunosuppressive peptides based on IL-10 inducing potential NNTox: Gene Ontology-Based Protein Toxicity Prediction Using Neural Network AllerCatPro-prediction of protein allergenicity potential from the protein sequence HLPpred-Fuse: improved and robust prediction of hemolytic peptide and its activity by fusing multiple feature representation A Method for Predicting Hemolytic Potency of Chemically Modified Peptides From Its Structure Novel in silico tools for designing peptide-based subunit vaccines and immunotherapeutics In Silico Tools and Databases for Designing Peptide-Based Vaccine and Drugs Severe acute respiratory syndrome coronavirus 2 data hub Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies Immunoinformatics-aided identification of T cell and B cell epitopes in the surface glycoprotein of 2019-nCoV Potential T-cell and B-cell Epitopes of A Sequence Homology and Bioinformatic Approach Can Predict Candidate Targets for Immune Responses to SARS-CoV-2 Human Leukocyte Antigen Susceptibility Map for Severe Acute Respiratory Syndrome Coronavirus 2 A web-based platform on COVID-19 to maintain Predicted Diagnostic, Drug and Vaccine candidates Speed coronavirus vaccine testing by deliberately infecting volunteers? Not so fast, some scientists warn Coronavirus crisis puts vaccine trials on the fast track The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.Copyright © 2020 Usmani and Raghava. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.